Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer).
Drug development describes the process of developing a new drug that effectively targets a specific weakness in a cell. This process involves specific pre-clinical development and testing, followed by trials in humans to determine the efficacy of the drug.
Glycoengineering of IgG antibodies and glycosite-specific antibody–drug conjugates is an important tool for enhancing their therapeutic efficacy. Tang et al. describe a protocol for efficient and homogeneous chemoenzymatic antibody glycoengineering.
Pittet and collaborators show that macrophages can remove anti-PD1 antibodies from T cells, blunting their response, whereas Weissman and colleagues demonstrate that macrophages also express PD1 on their surface, which impairs their phagocytic activity.